Immutep (IMMP) said Thursday its investigational drug eftilagimod alpha, or efti, combined with Merck's (MRK) Keytruda and doublet chemotherapy achieved a response rate of 60.8% and disease control rate of 90.2% in patients with advanced or metastatic non-squamous non-small cell lung cancer in an investigator-initiated trial.
The company said the 60.8% response rate regardless of PD-L1 expression is a "substantial improvement" from the historical control of 48%.
Safety continues to be favorable for the triple combination, the company said.
Immutep said it expects to present additional data from the trial at a medical conference within the year.
Shares of Immutep climbed 9.3% in recent premarket activity Thursday, while Merck shares added 1%.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。